Your browser doesn't support javascript.
Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study.
Borie, Raphael; Savale, Laurent; Dossier, Antoine; Ghosn, Jade; Taillé, Camille; Visseaux, Benoit; Jebreen, Kamel; Diallo, Abourahmane; Tesmoingt, Chloe; Morer, Lise; Goletto, Tiphaine; Faucher, Nathalie; Hajouji, Linda; Neukirch, Catherine; Phillips, Mathilde; Stelianides, Sandrine; Bouadma, Lila; Brosseau, Solenn; Ottaviani, Sébastien; Pluvy, Johan; Le Pluart, Diane; Debray, Marie-Pierre; Raynaud-Simon, Agathe; Descamps, Diane; Khalil, Antoine; Timsit, Jean Francois; Lescure, Francois-Xavier; Descamps, Vincent; Papo, Thomas; Humbert, Marc; Crestani, Bruno; Dieude, Philippe; Vicaut, Eric; Zalcman, Gérard.
  • Borie R; Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Savale L; Pulmonology Department, Kremlin-Bicêtre University Hospital, AP-HP, Paris-Saclay University, Kremlin-Bicêtre, France.
  • Dossier A; Internal Medicine Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Ghosn J; Infectious Disease Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Taillé C; Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Visseaux B; Virology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Jebreen K; Biostatistics and Clinical Research Department, University Hospital Lariboisière, AP-HP, Université de Paris, Paris, France.
  • Diallo A; Biostatistics and Clinical Research Department, University Hospital Lariboisière, AP-HP, Université de Paris, Paris, France.
  • Tesmoingt C; Pharmacy Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Morer L; Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Goletto T; Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Faucher N; Geriatrics Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Hajouji L; Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Neukirch C; Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Phillips M; Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Stelianides S; Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Bouadma L; Medical and infectious Diseases ICU, Intensive Care Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Brosseau S; Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Ottaviani S; Rheumatology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Pluvy J; Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Le Pluart D; Infectious Disease Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Debray MP; Radiology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Raynaud-Simon A; Pharmacy Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Descamps D; Virology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Khalil A; Radiology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Timsit JF; Medical and infectious Diseases ICU, Intensive Care Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Lescure FX; Infectious Disease Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Descamps V; Dermatology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Papo T; Internal Medicine Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Humbert M; Pulmonology Department, Kremlin-Bicêtre University Hospital, AP-HP, Paris-Saclay University, Kremlin-Bicêtre, France.
  • Crestani B; Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Dieude P; Rheumatology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
  • Vicaut E; Biostatistics and Clinical Research Department, University Hospital Lariboisière, AP-HP, Université de Paris, Paris, France.
  • Zalcman G; Pulmonology and Thoracic Oncology Department, University Hospital Bichat-Claude Bernard, AP-HP, Université de Paris, Paris, France.
PLoS One ; 15(12): e0243961, 2020.
Article in English | MEDLINE | ID: covidwho-978944
ABSTRACT

BACKGROUND:

The optimal treatment for patients with severe coronavirus-19 disease (COVID-19) and hyper-inflammation remains debated. MATERIAL AND

METHODS:

A cohort study was designed to evaluate whether a therapeutic algorithm using steroids with or without interleukin-1 antagonist (anakinra) could prevent death/invasive ventilation. Patients with a ≥5-day evolution since symptoms onset, with hyper-inflammation (CRP≥50mg/L), requiring 3-5 L/min oxygen, received methylprednisolone alone. Patients needing ≥6 L/min received methylprednisolone + subcutaneous anakinra daily either frontline or in case clinical deterioration upon corticosteroids alone. Death rate and death or intensive care unit (ICU) invasive ventilation rate at Day 15, with Odds Ratio (OR) and 95% CIs, were determined according to logistic regression and propensity scores. A Bayesian analysis estimated the treatment effects.

RESULTS:

Of 108 consecutive patients, 70 patients received glucocorticoids alone. The control group comprised 63 patients receiving standard of care. In the corticosteroid±stanakinra group (n = 108), death rate was 20.4%, versus 30.2% in the controls, indicating a 30% relative decrease in death risk and a number of 10 patients to treat to avoid a death (p = 0.15). Using propensity scores a per-protocol analysis showed an OR for COVID-19-related death of 0.9 (95%CI [0.80-1.01], p = 0.067). On Bayesian analysis, the posterior probability of any mortality benefit with corticosteroids+/-anakinra was 87.5%, with a 7.8% probability of treatment-related harm. Pre-existing diabetes exacerbation occurred in 29 of 108 patients (26.9%).

CONCLUSION:

In COVID-19 non-ICU inpatients at the cytokine release phase, corticosteroids with or without anakinra were associated with a 30% decrease of death risk on Day 15.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Methylprednisolone / Interleukin 1 Receptor Antagonist Protein / COVID-19 Drug Treatment / Glucocorticoids Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2020 Document Type: Article Affiliation country: Journal.pone.0243961

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Methylprednisolone / Interleukin 1 Receptor Antagonist Protein / COVID-19 Drug Treatment / Glucocorticoids Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2020 Document Type: Article Affiliation country: Journal.pone.0243961